Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Stefan O. Ochiana"'
Autor:
Alexander Bolaender, Danuta Zatorska, Huazhong He, Suhasini Joshi, Sahil Sharma, Chander S. Digwal, Hardik J. Patel, Weilin Sun, Brandon S. Imber, Stefan O. Ochiana, Maulik R. Patel, Liza Shrestha, Smit. K. Shah, Shuo Wang, Rashad Karimov, Hui Tao, Pallav D. Patel, Ananda Rodilla Martin, Pengrong Yan, Palak Panchal, Justina Almodovar, Adriana Corben, Andreas Rimner, Stephen D. Ginsberg, Serge Lyashchenko, Eva Burnazi, Anson Ku, Teja Kalidindi, Sang Gyu Lee, Milan Grkovski, Bradley J. Beattie, Pat Zanzonico, Jason S. Lewis, Steve Larson, Anna Rodina, Nagavarakishore Pillarsetty, Viviane Tabar, Mark P. Dunphy, Tony Taldone, Fumiko Shimizu, Gabriela Chiosis
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)
Here, the authors show structural, biochemical, and functional insights into the discovery of epichaperome‐ directed chemical probes for use in central nervous system diseases. Probes emerging from this work have translated to human clinical studie
Externí odkaz:
https://doaj.org/article/ed3d8f0c921541cb8291f5f96c64889e
Supplemental Figure 2 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
Supplemental Figure 2. Tumor PU-H71 retention at 24 hours post-injection (quantified by standard uptake value) is not explained by plasma radiotracer exposure (quantified by plasma AUC from 10 min to 4 h post-injection, see Methods), as indicated by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8112ce39ee10426f23c28886ea84aa71
https://doi.org/10.1158/1078-0432.22477815.v1
https://doi.org/10.1158/1078-0432.22477815.v1
Supplemental Figure 1 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
Supplemental Figure 1. Tumor retention of PU-H71 tracer varied considerably between patients. Tumor retention expressed as tumor:bloodpool SUV ratio (y-axis) measured on PET at 4 and 24 hours post tracer-injection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951f22e47aec50efd05d77b9ce89c91c
https://doi.org/10.1158/1078-0432.22477818.v1
https://doi.org/10.1158/1078-0432.22477818.v1
Supplemental Figure 3 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
Tumor PU-H71 retention at 24 hours post-injection (quantified by standard uptake value) is not explained by plasma radiotracer exposure (quantified by plasma AUC from 10 min to 4 h post-injection, see Methods), as indicated by Spearman Test R-value.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cecc57205e1427af5a87a0a2522a0a8
https://doi.org/10.1158/1078-0432.22477812.v1
https://doi.org/10.1158/1078-0432.22477812.v1
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
Supplementary figures and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d576fe517c9362b2fb6e5605fc2c2db2
https://doi.org/10.1158/1078-0432.22477803
https://doi.org/10.1158/1078-0432.22477803
Supplemental Figure 4 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
PET detects subcentimeter PU-H71 retention by breast cancer metastases. 65-year-old female with stage IV breast cancer, off-treatment. 124I-PU-H71 PET (right), CT (left), and fusion PET/CT (middle) images show corresponding axial planes of chest, obt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862ced035c01652e56fc9977633c016d
https://doi.org/10.1158/1078-0432.22477809.v1
https://doi.org/10.1158/1078-0432.22477809.v1
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
Purpose:124I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164f127edfb0119709b9665af34b1911
https://doi.org/10.1158/1078-0432.c.6529761
https://doi.org/10.1158/1078-0432.c.6529761
Supplemental Figure 5 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Autor:
Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, Hanwen Zhang, Josef J. Fox, Heiko M. Schöder, Jacqueline Bromberg, Clifford A. Hudis, Serge K. Lyashchenko, Eva M. Burnazi, Mohammad M. Uddin, Stefan O. Ochiana, Tony Taldone, Danuta Zatorska, Pat B. Zanzonico, Bradley J. Beattie, Larry Norton, Komal Jhaveri, Shanu Modi, Milan Grkovski, Nagavarakishore Pillarsetty, Christina Pressl, Mark P.S. Dunphy
PET detects PU-H71 retention by lymphoma. 62-year-old female with non-Hodgkin lymphoma. 124I-PU-H71 fusion PET/CT (left), CT (middle), and F-18 FDG fusion PET/CT (right) images show corresponding axial planes of chest. 124I-PU-H71 PET/CT obtained 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f7f92068c127f513a32922af584edc
https://doi.org/10.1158/1078-0432.22477806.v1
https://doi.org/10.1158/1078-0432.22477806.v1
Autor:
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, Tony Taldone, Eric Sturgill, Sarah Brennan, Stefan O. Ochiana, Erica M. Gomes-DaGama, Siddhartha Sen, Anna Rodina, John Koren III, Michael W. Becker, Charles M. Rudin, Ari Melnick, Ross L. Levine, Gail J. Roboz, Stephen D. Nimer, Gabriela Chiosis, Monica L. Guzman
Publikováno v:
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from relapsed disease. Irrespective of mutation status, the development of aggressive leukemias is en
Externí odkaz:
https://doaj.org/article/03d9a17749844c7d85caa19fad88d006
Autor:
Serge K. Lyashchenko, Mark Dunphy, Danuta Zatorska, Hanwen Zhang, Eva Burnazi, Heiko Schöder, Pat Zanzonico, Milan Grkovski, Tony Taldone, Bradley J. Beattie, Christina Pressl, Steven M. Larson, Jason S. Lewis, Stefan O. Ochiana, Josef J. Fox, Jacqueline Bromberg, Komal Jhaveri, Nagavarakishore Pillarsetty, Mohammad M. Uddin, Larry Norton, Shanu Modi, Gabriela Chiosis, Clifford A. Hudis
Publikováno v:
Clinical Cancer Research. 26:5178-5187
Purpose: 124I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conduct